Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › evolocumab

evolocumab

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of evolocumab

46 trials tracked of evolocumab: 31 in phase 3 or 4 and 21 with published results. The most-cited published study has 1491 citations.

46Trials tracked
31Phase 3 & 4
0Recruiting
21With published results
Phase distribution
Phase 4 5 Phase 3 26 Phase 2 12 Phase 1 3
  1. Phase 3 Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia Completed · 1,491 cited
  2. Phase 3 GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound Completed · 1,149 cited
  3. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 Completed · 511 cited
  4. Phase 3 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects Completed · 481 cited
  5. Phase 3 Imaging of Coronary Plaques in Participants Treated With Evolocumab Completed · 426 cited
  6. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension Completed · 378 cited
Show 40 more trials
  1. Phase 3 Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders Completed · 330 cited
  2. Phase 3 Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders Completed · 189 cited
  3. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed · 169 cited
  4. Phase 3 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody Completed · 147 cited
  5. Phase 4 Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes Completed · 142 cited
  6. Phase 3 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) Completed · 126 cited
  7. Phase 3 Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia Completed · 126 cited
  8. Phase 3 Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Completed · 71 cited
  9. Phase 3 Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) Completed · 48 cited
  10. Phase 3 Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia Completed · 32 cited
  11. Phase 4 Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia Completed · 31 cited
  12. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 Completed · 29 cited
  13. Phase 3 Effect of Evolocumab on Coronary Atherosclerosis Completed · 14 cited
  14. Phase 4 Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity Completed · 12 cited
  15. Phase 4 The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease Completed · 10 cited
  16. Phase 4 Lipid Management in Renal Transplant Recipients Using Evolocumab. Completed
  17. Phase 3 Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment Completed
  18. Phase 3 Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab Completed
  19. Phase 3 Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities Completed
  20. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 Completed
  21. Phase 3 Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 Completed
  22. Phase 3 Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk Completed
  23. Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed
  24. Phase 3 Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 Completed
  25. Phase 3 Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study Completed
  26. Phase 2 Evolocumab in Acute Coronary Syndrome Completed
  27. Phase 2 Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels Completed
  28. Phase 2 An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol Completed
  29. Phase 2 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy Completed
  30. Phase 2 Effect of Evolocumab on Coronary Endothelial Function Completed
  31. Phase 2 Open Label Study of Long Term Evaluation Against LDL-C Trial Completed
  32. Phase 2 A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects Completed
  33. Phase 2 Evolocumab in Patients With Acute MI Completed
  34. Phase 2 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects Completed
  35. Phase 2 Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study Completed
  36. Phase 2 Impact of Evolocumab in Cardiac Transplant Patients With CAV Completed
  37. Phase 2 LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy Completed
  38. Phase 1 Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin Completed
  39. Phase 1 Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors Completed
  40. Phase 1 Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab Completed

Showing the 46 most-cited and recently-updated of 46 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Evolocumab reduces MACE by 29% in patients with BMI greater than or equal to 35 kg/m
Diabetes & Endocrinology RCT
Evolocumab reduces MACE by 29% in patients with BMI greater than or equal to 35 kg/m Evolocumab shows greater heart protection for patients with higher BMI
This randomized controlled trial of 27,564 stable atherosclerotic cardiovascular disease patients found that evolocumab significantly reduce…
A large study finds that the heart medication evolocumab provides significantly more protection against heart attacks and strokes for patien…
Jun 9, 2026
Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis
Cardiology RCT
Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis Evolocumab cuts heart events in high-risk diabetes patients
This prespecified subgroup analysis of a phase 3 RCT evaluated evolocumab added to statin therapy in 3655 high-risk patients with type 2 dia…
Adding evolocumab to statins reduced heart attacks and strokes by about 30% in high-risk diabetes patients without known heart disease.
JAMA Jun 4, 2026
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia
Drug Pipeline Sys. Review
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia Review explores PCSK9 inhibitors for familial hypercholesterolemia
This narrative review synthesizes evidence on PCSK9 inhibitors, including evolocumab, for familial hypercholesterolemia. The authors discuss…
This review looks at PCSK9 inhibitors like evolocumab for people with familial hypercholesterolemia. It discusses how these drugs work and t…
Frontiers May 27, 2026
Phase 4 study of evolocumab safety and tolerability in renal transplant recipients
Diabetes & Endocrinology Phase IV
Phase 4 study of evolocumab safety and tolerability in renal transplant recipients Can a new cholesterol drug help kidney transplant patients without causing harm?
This Phase 4 study evaluated the safety and tolerability of evolocumab, a PCSK-9 inhibitor, in renal transplant recipients at three hospital…
A new cholesterol injection kept kidney transplant patients safe for over two years without serious side effects, offering a potential alter…
CT.gov Apr 17, 2026
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD
Cardiology Phase III
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD Re-analysis suggests most PCSK9 inhibitor benefit comes from lowering Lp(a)
This Phase 3 corrective re-analysis of cardiovascular outcomes trial data in secondary prevention populations with ASCVD evaluated the role …
Researchers re-analyzed data from Phase 3 trials of alirocumab and evolocumab in patients with atherosclerotic cardiovascular disease.
medRxiv Apr 16, 2026